CNS PHARMACEUTICALS, INC.

2100 WEST LOOP SOUTH

SUITE 900

HOUSTON TX 77027

 

 

October 2, 2020

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

 

Re:CNS Pharmaceuticals, Inc.
  Registration Statement on Form S-1
  Registration No. 333-249068

 

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30 P.M. (Eastern Time) on October 6, 2020, or as soon thereafter as possible on such date.

 

 

  Very truly yours,
   
  CNS Pharmaceuticals, Inc.
   
  By: /s/ Christopher Downs                                  
  Name: Christopher Downs
  Title: Chief Financial Officer